LLY

917.8

+1.65%↑

JNJ

241.24

+2.67%↑

ABBV

207.5

+1%↑

NVS

151.15

+1.78%↑

MRK

119.73

+3.2%↑

LLY

917.8

+1.65%↑

JNJ

241.24

+2.67%↑

ABBV

207.5

+1%↑

NVS

151.15

+1.78%↑

MRK

119.73

+3.2%↑

LLY

917.8

+1.65%↑

JNJ

241.24

+2.67%↑

ABBV

207.5

+1%↑

NVS

151.15

+1.78%↑

MRK

119.73

+3.2%↑

LLY

917.8

+1.65%↑

JNJ

241.24

+2.67%↑

ABBV

207.5

+1%↑

NVS

151.15

+1.78%↑

MRK

119.73

+3.2%↑

LLY

917.8

+1.65%↑

JNJ

241.24

+2.67%↑

ABBV

207.5

+1%↑

NVS

151.15

+1.78%↑

MRK

119.73

+3.2%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Atvērts

36.89 6.37

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

34.2

Max

36.98

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+48.4% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	140M 5.7B
Iepriekšējā atvēršanas cena	30.52
Iepriekšējā slēgšanas cena	36.89

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. marts 18:58 UTC

Galvenie tirgus virzītāji

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

2026. g. 24. marts 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 24. marts 23:48 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 24. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises, Boosted by Dollar Weakness -- Market Talk

2026. g. 24. marts 23:16 UTC

Tirgus saruna

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

2026. g. 24. marts 21:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. marts 21:44 UTC

Tirgus saruna

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

2026. g. 24. marts 20:59 UTC

Peļņas

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

2026. g. 24. marts 20:58 UTC

Galvenie ziņu notikumi

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 24. marts 20:25 UTC

Peļņas

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

2026. g. 24. marts 20:15 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Commodities Roundup: Market Talk

2026. g. 24. marts 20:10 UTC

Tirgus saruna

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q Sales $378.7M >WOR

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q Adj EPS 98c >WOR

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q EPS 92c >WOR

2026. g. 24. marts 19:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

2026. g. 24. marts 19:06 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

2026. g. 24. marts 18:51 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

2026. g. 24. marts 18:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 24. marts 18:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

2026. g. 24. marts 18:34 UTC

Galvenie ziņu notikumi

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

2026. g. 24. marts 18:27 UTC

Tirgus saruna

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

2026. g. 24. marts 18:21 UTC

Tirgus saruna

Galvenie ziņu notikumi

Silver Snaps 9-Session Losing Streak -- Market Talk

2026. g. 24. marts 18:00 UTC

Iegādes, apvienošanās, pārņemšana

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

48.4% augšup

Prognoze 12 mēnešiem

Vidējais 52.55 USD 48.4%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.